You Searched For "aducanumab" and got 20 results
Sort By:
3 mins read
Medicare sticks by decision to limit coverage of a controversial Alzheimer's drug to people involved in clinical trials
The Medicare coverage decision is a blow for Biogen, which has struggled with sales of its new drug…
Allison DeAngelis
2 mins read
The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show
The director of the FDA's biostatistics office said there wasn't enough evidence to approve Aduhelm…
Allison DeAngelis
2 mins read
The FDA is delaying a controversial Alzheimer's drug decision. Analysts say that's a good sign.
The FDA has extended its deadline to approve or reject Biogen's drug by three months. Analysts say …
Allison DeAngelis
1 min read
The FDA approved a drug to treat the underlying cause of Alzheimer's and potentially slow its progression. But not all doctors are willing to prescribe it.
Although far from a cure, aducanumab could mark a new era in treating the leading cause of dementia…
Alex Hickey, Morning Brew
1 min read
Biogen jumps 6% ahead of a key FDA decision for its Alzheimer's drug
The second phase 3 trial for Biogen's aducanumab failed to meet its primary and secondary endpoints…
Matthew Fox
1 min read
Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee
The committee voted 8-1 that data from a Biogen study evaluating patients with mild Alzheimer's was…
Matthew Fox
1 min read
Biogen soars 47% after FDA scientists say its Alzheimer's drug's efficacy is 'exceptionally persuasive'
Biogen's drug aducanumab, which was jointly developed with Japan's Eisai, will receive an FDA appro…
Matthew Fox
4 mins read
The FDA just approved the first new Alzheimer's drug in 18 years
The Food and Drug Administration approved Biogen's Alzheimer's disease treatment even though outsid…
Allison DeAngelis
2 mins read
Years of Alzheimer's research were based on a key finding. Now an investigation alleges it was faked, and the work may have been wasted.
A seminal 2006 paper contains manipulated data, an investigation from Science alleges. More than 2,…
Marianne Guenot
1 min read
Eli Lilly falls 9% after its Alzheimer's drug data underwhelms Wall Street
A successful Alzheimer's drug has been viewed as the holy grail in biotech, as it would combat a de…
Matthew Fox
5 mins read
Biogen is submitting a key Alzheimer's drug it once abandoned for approval 'as soon as possible.' Here's what we just learned and still need to know.
The Cambridge, Massachusetts-based biotech shocked the Alzheimer's research community and drug indu…
Andrew Dunn
1 min read
Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years
The FDA approval marks the first treatment cleared by US regulators to decelerate cognitive decline…
Isabelle Lee
2 mins read
The promise of the first new Alzheimer's drug in nearly 2 decades
These are Business Insider's biggest healthcare stories for November 5.
Lydia Ramsey Pflanzer
3 mins read
Pfizer says its coronavirus vaccine works
These are Business Insider's biggest healthcare stories for November 9.
Lydia Ramsey Pflanzer
4 mins read
An election week for the history books
These are the top stories written by Business Insider's healthcare team for the week ending Novembe…
Lydia Ramsey Pflanzer
2 mins read
Biogen falls 8% after 2 major hospital systems say they won't administer controversial Alzheimer's drug
The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs o…
Matthew Fox
3 mins read
Biogen has seen $19 billion wiped out since a promising drug flopped - and one analyst has a bold idea for how the biotech pioneer can recover
Competitive challenges have also compounded the company's recent failure. After Biogen reported fin…
Emma Court
1 min read
A $44 billion biotech just got some good news from the FDA about a key Alzheimer's drug, and the stock is soaring
Biogen and Eisai said their experimental Alzheimer's treatment will be reviewed more quickly by reg…
Barbara Smith
2 mins read
A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug
Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the wors…
Erin Snodgrass
1 min read
Morgan Stanley double-upgrades Biogen and says the stock can surge another 30%
"While BIIB remains a high-risk/ high-reward stock, we think now is the right time to take the risk…